The use of testosterone therapy has a complex history of apprehension and questions regarding its safety. Despite an eventual consensus that testosterone therapy was safe and effective, several studies relating to cardiovascular risks emerged in the last decade, rekindling skepticism regarding the safety of testosterone therapy. Given the utility of testosterone therapy in treating the symptoms of hypogonadism, it remains crucial to closely examine the safety of testosterone therapy. The present article synthesizes the current evidence regarding cardiovascular risks that may be associated with testosterone therapy, the potential mechanisms regarding testosterone’s efficacy, and future directions in evaluating the safety of its use.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $14.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Tsametis CP, Isidori AM. Testosterone replacement therapy: for whom, when and how?. Metabolism. 2018;86:69–78. https://doi.org/10.1016/j.metabol.2018.03.007.
Smith JB, Rosen J, Colbert A. Low serum testosterone in outpatient psychiatry clinics: addressing challenges to the screening and treatment of hypogonadism. Sex Med Rev. 2018;6:69–76. https://doi.org/10.1016/j.sxmr.2017.08.007.
Dohle G, Arver S, Bettocchi C, Jones T, Kliesch S, Punab M. Guidelines on male hypogonadism. Eur Assoc Urol. 2015. https://doi.org/10.1007/978-1-60761-193-6.
Huggins C, Hodges CV. Studies on prostatic cancer i. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;22:232–40. https://doi.org/10.3322/canjclin.22.4.232.
Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170–83. https://doi.org/10.1093/jnci/djm323.
Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482–92. https://doi.org/10.1056/NEJMra022251.
Morgentaler A, Traish A. The history of testosterone and the evolution of its therapeutic potential. Sex Med Rev. 2020;8:286–96. https://doi.org/10.1016/j.sxmr.2018.03.002.
Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90:224–51. https://doi.org/10.1016/j.mayocp.2014.10.011.
Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N. Engl J Med. 2010;363:109–22. https://doi.org/10.1056/NEJMoa1000485.
US Food and Drug Administration. Citizen petition denial response from FDA CDER to public citizen. 2014. http://www.citizen.org/documents/2184_FDA%20Denial%20of%20Petition_July%.2016%202014.pdf. Accessed April 28, 2016.
Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA - J Am Med Assoc. 2013;310:1829–36. https://doi.org/10.1001/jama.2013.280386.
Morgentaler A, Lunenfeld B. Testosterone and cardiovascular risk: World’s experts take unprecedented action to correct misinformation. Aging Male. 2014;17:63–65. https://doi.org/10.3109/13685538.2014.913413.
Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805 https://doi.org/10.1371/journal.pone.0085805.
Woodcock J. Letter to Sidney Wolfe, M.D. and Michael Carome, M.D., responding to FDA-2014-P-0258, Public Citizen’s petition for boxed warning for testosterone-containing drugs. Food and Drug Administration. 2014. https://www.citizen.org/wp-content/uploads/migration/2184_fda_denial_of_petition_july_16_2014.pdf. Accessed June 2020.
Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108 https://doi.org/10.1186/1741-7015-11-108.
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm.
European Medicines Agency. No consistent evidence of an increased risk of heart problems with testosterone medicines. 87, 3632–9. www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/11/WC500177618.pdf. Accessed June, 2020.
Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423–32. https://doi.org/10.1016/j.juro.2018.03.115.
Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an endocrine society. J Clin Endocrinol Metab. 2018;103:1715–44. https://doi.org/10.1210/jc.2018-00229.
Soisson V, Brailly-Tabard S, Helmer C, Rouaud O, Ancelin ML, Zerhouni C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013;75:282–8. https://doi.org/10.1016/j.maturitas.2013.04.012.
Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007–19. https://doi.org/10.1210/jc.2011-1137.
Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96:1821–5. https://doi.org/10.1136/hrt.2010.195412.
Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men: The MrOS (osteoporotic fractures in men) study in Sweden. J Am Coll Cardiol. 2011;58:1674–81. https://doi.org/10.1016/j.jacc.2011.07.019.
Hak AE, Witteman JCM, de Jong FH, Geerlings MI, Hofman A, Pols HAP. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the rotterdam study. J Clin Endocrinol Metab. 2002;87:3632–9. https://doi.org/10.1210/jcem.87.8.8762.
Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15:1260–71. https://doi.org/10.1016/j.jsxm.2018.06.012.
Adelborg K, Rasmussen TB, Nørrelund H, Layton JB, Sørensen HT, Christiansen CF. Cardiovascular outcomes and all-cause mortality following measurement of endogenous testosterone levels. Am J Cardiol. 2019;123:1757–64. https://doi.org/10.1016/j.amjcard.2019.02.042.
Karakas M, Schäfer S, Appelbaum S, Ojeda F, Kuulasmaa K, Brückmann B, et al. Testosterone levels and type 2 diabetes—No correlation with age, differential predictive value in men and women. Biomolecules. 2018;8:76 https://doi.org/10.3390/biom8030076.
Zeller T, Schnabel RB, Appelbaum S, Ojeda F, Berisha F, Schulte-Steinberg B, et al. Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women – results from the FINRISK study. Eur J Prev Cardiol. 2018;25:1133–9. https://doi.org/10.1177/2047487318778346.
Zeller T, Appelbaum S, Kuulasmaa K, Palosaari T, Blankenberg S, Jousilahti P, et al. Predictive value of low testosterone concentrations regarding coronary heart disease and mortality in men and women – evidence from the FINRISK97 study. J Intern Med. 2019;286:317–25. https://doi.org/10.1111/joim.12943.
Yeap BB, Alfonso H, Paul Chubb SA, Handelsman DJ, Hankey GJ, Almeida OP, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab. 2014;99:E9–E18. https://doi.org/10.1210/jc.2013-3272.
Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen TP, Haring R, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. PLoS One. 2014;9:e100409 https://doi.org/10.1371/journal.pone.0100409.
Lamm S, Chidakel A, Bansal R. Obesity and hypogonadism. Urol Clin North Am. 2016;43:239–45. https://doi.org/10.1016/j.ucl.2016.01.005.
O’Reilly MW, Glisic M, Kumarendran B, Subramanian A, Manolopoulos KN, Tahrani AA, et al. Serum testosterone, sex hormone-binding globulin and sex-specific risk of incident type 2 diabetes in a retrospective primary care cohort. Clin Endocrinol. 2019;90:145–54. https://doi.org/10.1111/cen.13862.
Liu X, Jiang J, Liu X, Luo Z, Wang Y, Dong X, et al. Association of serum testosterone with different classes of glucose metabolism and the mediation effect of obesity: the Henan Rural Cohort Study. Diabetes Metab Res Rev. 2019;35:3133 https://doi.org/10.1002/dmrr.3133.
Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with Type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828–37. https://doi.org/10.2337/dc10-1233.
Sharma R, Oni OA, Gupta K, Chen G, Sharma M, Dawn B, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–15. https://doi.org/10.1093/eurheartj/ehv346.
Sharma R, Oni OA, Gupta K, Sharma M, Sharma R, Singh V, et al. Normalization of testosterone levels after testosterone replacement therapy is associated with decreased incidence of atrial fibrillation. J Am Heart Assoc. 2017;6. https://doi.org/10.1161/JAHA.116.004880.
Oni OA, Sharma R, Chen G, Sharma M, Gupta K, Dawn B, et al. Normalization of testosterone levels after testosterone replacement therapy is not associated with reduced myocardial infarction in smokers. Mayo Clin Proc Innov Qual Outcomes. 2017;1:57–66. https://doi.org/10.1016/j.mayocpiqo.2017.05.003.
Etminan M, Skeldon SC, Goldenberg SL, Carleton B, Brophy JM. Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study. Pharmacotherapy. 2015;35:72–8. https://doi.org/10.1002/phar.1534.
Wallis CJD, Lo K, Lee Y, Krakowsky Y, Garbens A, Satkunasivam R, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: An intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016;4:498–506. https://doi.org/10.1016/S2213-8587(16)00112-1.
Traish AM, Haider A, Haider KS, Doros G, Saad F. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism. J Cardiovasc Pharm Ther. 2017;22:414–33. https://doi.org/10.1177/1074248417691136.
Cheetham TC, An JJ, Jacobsen SJ, Niu F, Sidney S, Quesenberry CP, et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med. 2017;177:491–9. https://doi.org/10.1001/jamainternmed.2016.9546.
Saad F, Caliber M, Doros G, Haider KS, Haider A. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male. 2020;23:81–92. https://doi.org/10.1080/13685538.2019.1575354.
Zhang X, Huang K, Saad F, Haider KS, Haider A, Xu X. Testosterone Therapy Reduces Cardiovascular Risk Among Hypogonadal Men: A Prospective Cohort Study in Germany. Androg Clin Res Ther. 2021;2:64–72. https://doi.org/10.1089/andro.2020.0015.
Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease (TRANSCEND) and the ongoing telmisartan alone and in combinatio. Circulation. 2012;126:934–41. https://doi.org/10.1161/CIRCULATIONAHA.111.086660.
Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids. 1990;55:330–52. https://doi.org/10.1016/0039-128X(90)90058-J.
Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res. 1999;84:813–9. https://doi.org/10.1161/01.RES.84.7.813.
Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: An effect that is independent of the classic androgen receptor. Circulation. 2007;116:2427–34. https://doi.org/10.1161/CIRCULATIONAHA.107.708768.
Bourghardt J, Wilhelmson ASK, Alexanderson C, De Gendt K, Verhoeven G, Krettek A, et al. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology. 2010;151:5428–37. https://doi.org/10.1210/en.2010-0663.
Iannantuoni F, Salazar JD, Martinez de Marañon A, Bañuls C, López-Domènech S, Rocha M, et al. Testosterone administration increases leukocyte-endothelium interactions and inflammation in transgender men. Fertil Steril. 2021;115:483–9. https://doi.org/10.1016/j.fertnstert.2020.08.002.
Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313–8. https://doi.org/10.1210/jc.2003-031069.
Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16:581–606. https://doi.org/10.1111/obr.12282.
Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39. https://doi.org/10.4065/82.1.29.
Langer C, Gansz B, Goepfert C, Engel T, Uehara Y, Von Dehn G, et al. Testosterone up-regulates scavenger receptor bi and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun. 2002;296:1051–7. https://doi.org/10.1016/S0006-291X(02)02038-7.
Movérare-Skrtic S, Venken K, Andersson N, Lindberg MK, Svensson J, Swanson C, et al. Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity. 2006;14:662–72. https://doi.org/10.1038/oby.2006.75.
Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092–8. https://doi.org/10.1210/jcem.75.4.1400877.
Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6:77–85. https://doi.org/10.1016/j.sxmr.2017.04.001.
Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab. 2010;95:4743–7. https://doi.org/10.1210/jc.2010-0864.
Angelova P, Momchilova A, Petkova D, Staneva G, Pankov R, Kamenov Z. Testosterone replacement therapy improves erythrocyte membrane lipid composition in hypogonadal men. Aging Male. 2012;15:173–9. https://doi.org/10.3109/13685538.2012.693550.
Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI. Comparison of the effects of testosterone gels, injections, and pellets on serum hormones, erythrocytosis, lipids, and prostate-specific antigen. Sex Med. 2015;3:165–73. https://doi.org/10.1002/sm2.76.
Eleawa SM, Sakr HF, Hussein AM, Assiri AS, Bayoumy NMK, Alkhateeb M. Effect of testosterone replacement therapy on cardiac performance and oxidative stress in orchidectomized rats. Acta Physiol. 2013;209:136–47. https://doi.org/10.1111/apha.12158.
Golden KL, Marsh JD, Jiang Y, Moulden J. Acute actions of testosterone on contractile function of isolated rat ventricular myocytes. Eur J Endocrinol. 2005;152:479–83. https://doi.org/10.1530/eje.1.01845.
Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation. 2005;112:1701–10. https://doi.org/10.1161/CIRCULATIONAHA.104.523217.
Zhang Y, Ouyang P, Post WS, Dalal D, Vaidya D, Blasco-Colmenares E, et al. Sex-steroid hormones and electrocardiographic qt-interval duration: findings from the third national health and nutrition examination survey and the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2011;174:403–11. https://doi.org/10.1093/aje/kwr172.
Vicente J, Johannesen L, Galeotti L, Strauss DG. Mechanisms of sex and age differences in ventricular repolarization in humans. Am Heart J. 2014;168:749–.e3. https://doi.org/10.1016/j.ahj.2014.07.010.
Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, et al. Hypogonadism as a reversible cause of torsades de pointes in men. Circulation. 2018;138:110–3. https://doi.org/10.1161/CIRCULATIONAHA.118.034282.
Malkin CJ, Pugh PJ, West JN, Van Beek EJR, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006;27:57–64. https://doi.org/10.1093/eurheartj/ehi443.
Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54:919–27. https://doi.org/10.1016/j.jacc.2009.04.078.
Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Heart. 1977;39:1217–22. https://doi.org/10.1136/hrt.39.11.1217.
Rosano GMC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1666–70. https://doi.org/10.1161/01.CIR.99.13.1666.
Webb CM, Adamson DL, De Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 1999;83:437–9. https://doi.org/10.1016/S0002-9149(98)00880-7.
Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–6. https://doi.org/10.1136/hrt.2003.021121.
Mathur A, Malkin C, Saeed B, Muthusamy R, Hugh Jones T, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161:443–9. https://doi.org/10.1530/EJE-09-0092.
English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chromic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906–11. https://doi.org/10.1161/01.CIR.102.16.1906.
Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. 2004;90:446–7. https://doi.org/10.1136/hrt.2003.014639.
Stout M, Tew GA, Doll H, Zwierska I, Woodroofe N, Channer KS, et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: A double-blind randomized controlled feasibility study. Am Heart J. 2012;164:893–901. https://doi.org/10.1016/j.ahj.2012.09.016.
Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015;100:2956–62. https://doi.org/10.1210/jc.2014-4434.
Basaria S, Travison TG, Alford D, Knapp PE, Teeter K, Cahalan C, et al. Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain. 2015;156:280–8. https://doi.org/10.1097/01.j.pain.0000460308.86819.aa.
Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39:82–91. https://doi.org/10.2337/dc15-1518.
Konaka H, Sugimoto K, Orikasa H, Iwamoto T, Takamura T, Takeda Y, et al. Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: A multicenter randomized controlled trial in Japan (EARTH Study). Asian J Androl. 2016;18:25–34. https://doi.org/10.4103/1008-682X.148720.
Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA - J Am Med Assoc. 2014;311:271–8. https://doi.org/10.1001/jama.2013.282535.
Park HB, Heo R, Ó Hartaigh B, Cho I, Gransar H, Nakazato R, et al. Atherosclerotic plaque characteristics by CT angiography identify coronary lesions that cause ischemia: a direct comparison to fractional flow reserve. JACC Cardiovasc Imaging. 2015;8:1–10. https://doi.org/10.1016/j.jcmg.2014.11.002.
Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with lowor low-normal testosterone levels: a randomized clinical trial. JAMA - J Am Med Assoc. 2015;314:570 https://doi.org/10.1001/jama.2015.8881.
Rastrelli G, Dicuio M, Reismann Y, Sforza A, Maggi M, Corona G. Cardiovascular impact of testosterone therapy for hypogonadism. Expert Rev Cardiovasc Ther. 2018;16:617–25. https://doi.org/10.1080/14779072.2018.1510314.
Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-Analysis. Expert Opin Drug Saf. 2014;13:1327–51. https://doi.org/10.1517/14740338.2014.950653.
Alexander GC, Iyer G, Lucas E, Lin D, Singh S. Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis. Am J Med. 2017;130:293–305. https://doi.org/10.1016/j.amjmed.2016.09.017.
Kloner RA, Carson C, Dobs A, Kopecky S, Mohler ER. Testosterone and cardiovascular disease. J Am Coll Cardiol. 2016;67:545–57. https://doi.org/10.1016/j.jacc.2015.12.005.
Layton JB, Meier CR, Sharpless JL, Stürmer T, Jick SS, Brookhart MA. Comparative safety of testosterone dosage forms. JAMA Intern Med. 2015;175:1187–96. https://doi.org/10.1001/jamainternmed.2015.1573.
Kharaba ZJ, Buabeid MA, Ibrahim NA, Jirjees FJ, Obaidi HJA, Kaddaha A, et al. Testosterone therapy in hypogonadal patients and the associated risks of cardiovascular events. Biomed Pharmacother. 2020;129:110423 https://doi.org/10.1016/j.biopha.2020.110423.
Kharaba ZJ, Buabeid MA, Alfoteih YA. Effectiveness of testosterone therapy in hypogonadal patients and its controversial adverse impact on the cardiovascular system. Crit Rev Toxicol. 2020;50:491–512. https://doi.org/10.1080/10408444.2020.1789944
Auerbach JM, Khera M. Hypogonadism management and cardiovascular health. Postgrad Med. 2020;132:35–41. https://doi.org/10.1080/00325481.2020.1805917.
Khera M, Miner M, Jaffe J, Pastuszak AW. Testosterone therapy and cardiovascular risk: a critical analysis of studies reporting increased risk. J Sex Med. 2021;18:83–98. https://doi.org/10.1016/j.jsxm.2020.10.019.
Ahmed T, Alattar M, Pantalone K, Haque R. Is testosterone replacement safe in men with cardiovascular disease? Cureus. 2020;12:7324 https://doi.org/10.7759/cureus.7324.
Sesti F, Pofi R, Minnetti M, Tenuta M, Gianfrilli D, Isidori AM. Late-onset hypogonadism: reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. Andrology. 2020;8:1614–27. https://doi.org/10.1111/andr.12876.
Corona G, Torres LO, Maggi M. Testosterone therapy: what we have learned from trials. J Sex Med. 2020;17:447–60. https://doi.org/10.1016/j.jsxm.2019.11.270.
US National Library of Medicine. ClinicalTrials.gov. 2019. http://www.clinicaltrials.gov/ct2/show/NCT03518034.
MK, MD, MBA, MPH. Consultant: Clarus, Boston Scientific, Metuchen, AbbVie. JA declares no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Auerbach, J.M., Khera, M. Testosterone replacement therapy and cardiovascular disease. Int J Impot Res 34, 685–690 (2022). https://doi.org/10.1038/s41443-021-00516-6
This article is cited by
International Journal of Impotence Research (2022)